Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuria

•Asymptomatic microhematuria is a frequent condition and triggers invasive workup.•Current guideline recommendations lack sufficient discriminatory capacity to spare patients from unnecessary interventions.•Development and validation of a nomogram, potentially including urine markers, is recommended...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Urologic oncology 2023-05, Vol.41 (5), p.254.e1-254.e8
Hauptverfasser: Kuckuck, Eva Charlotte, Hennenlotter, Jörg, Todenhöfer, Tilman, Brünn, Lenuta-Ancuta, Rass, Georg-Christian, Stenzl, Arnulf, Hakenberg, Oliver W., Roghmann, Florian, Goebell, Peter J., Grimm, Marc-Oliver, Pycha, Armin, Bolenz, Christian, Burger, Maximilian, Benderska-Söder, Natalya, Schmitz-Dräger, Bernd J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 254.e8
container_issue 5
container_start_page 254.e1
container_title Urologic oncology
container_volume 41
creator Kuckuck, Eva Charlotte
Hennenlotter, Jörg
Todenhöfer, Tilman
Brünn, Lenuta-Ancuta
Rass, Georg-Christian
Stenzl, Arnulf
Hakenberg, Oliver W.
Roghmann, Florian
Goebell, Peter J.
Grimm, Marc-Oliver
Pycha, Armin
Bolenz, Christian
Burger, Maximilian
Benderska-Söder, Natalya
Schmitz-Dräger, Bernd J.
description •Asymptomatic microhematuria is a frequent condition and triggers invasive workup.•Current guideline recommendations lack sufficient discriminatory capacity to spare patients from unnecessary interventions.•Development and validation of a nomogram, potentially including urine markers, is recommended. Asymptomatic microhematuria (aMh) remains a diagnostic challenge in urological practice: while aMh is a risk factor of urothelial carcinoma (UC), prevalence of aMh is high. Guidelines were developed to permit risk stratification and reduce diagnostic workload. This study investigates the efficacy of several recommendations. Sixty hundred eight patients with newly diagnosed aMh without previous UC from an academic referral center (A; n = 320) and a private outpatient clinic (B; n = 288) were included. All patients underwent clinical workup including medical history, urine cytology, upper tract imaging and cystoscopy. Eleven former and current guidelines were applied to each patient individually; every patient was classified as either low risk (no further workup recommended) or high risk. Furthermore, a recently developed nomogram for hematuria assessment was included. The cohort comprised 142 females and 466 males (mean age 62 [range 18–92] years). Sixty-one patients (10.0%) were diagnosed with UC. Excluding the Swedish and recent NICE guideline generally advising against urologic workup, application of 9 other recommendations would have diagnosed all UCs and saved 1.6% to 16.1% of patients from workup. For the 2020 US guideline, solely applied to cohort B, 10.6% of patients were classified as low risk. The use of the nomogram would have saved 17.1% to 25% of patients from workup. Practical relevance of current guidelines is limited as they do not sufficiently identify patients not requiring clinical work up. Thus, guideline adherence may trigger overdiagnosis and even overtreatment. New ways of risk stratification are needed to improve aMh assessment.
doi_str_mv 10.1016/j.urolonc.2022.08.011
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2728146956</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1078143922003040</els_id><sourcerecordid>2728146956</sourcerecordid><originalsourceid>FETCH-LOGICAL-c313t-3ccd2367a29aa877492e46b7ecc78aeeec460244534715b6d898d3078e714d393</originalsourceid><addsrcrecordid>eNqFkEuPFCEQgInRuA_9CRqOXrrlNUCfjNnV1WQTL3omDNQ4TLqbFug18--tyYxePVFUfUVRHyFvOOs54_r9oV9LHvMcesGE6JntGefPyDW3RnZCDfo5xszYjis5XJGbWg-McWU5f0mupBZGMTFck3qfaihpSrNv6Qlo8IsPqR1p3tGfa4owphlogZCnCeaIUJ4rTTNte6C-VqgV8-2EL1jEsNLfqe2xdpyWlidMBjqlUPIe8LKW5F-RFzs_Vnh9OW_Jj8-fvt996R6_PXy9-_jYBcll62QIUUhtvBi8t8aoQYDSWwMhGOsBICjNhFIbqQzfbHW0g40SVwbDVZSDvCXvzu8uJf9aoTY34bIwjn6GvFYnjLBc6WGjEd2cUfxnrQV2bkEpvhwdZ-7k2x3cxbc7-XbMOvSNfW8vI9btBPFf11_BCHw4A4CLPiUorga0FCAmlNpczOk_I_4AA2KXFw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2728146956</pqid></control><display><type>article</type><title>Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuria</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Kuckuck, Eva Charlotte ; Hennenlotter, Jörg ; Todenhöfer, Tilman ; Brünn, Lenuta-Ancuta ; Rass, Georg-Christian ; Stenzl, Arnulf ; Hakenberg, Oliver W. ; Roghmann, Florian ; Goebell, Peter J. ; Grimm, Marc-Oliver ; Pycha, Armin ; Bolenz, Christian ; Burger, Maximilian ; Benderska-Söder, Natalya ; Schmitz-Dräger, Bernd J.</creator><creatorcontrib>Kuckuck, Eva Charlotte ; Hennenlotter, Jörg ; Todenhöfer, Tilman ; Brünn, Lenuta-Ancuta ; Rass, Georg-Christian ; Stenzl, Arnulf ; Hakenberg, Oliver W. ; Roghmann, Florian ; Goebell, Peter J. ; Grimm, Marc-Oliver ; Pycha, Armin ; Bolenz, Christian ; Burger, Maximilian ; Benderska-Söder, Natalya ; Schmitz-Dräger, Bernd J.</creatorcontrib><description>•Asymptomatic microhematuria is a frequent condition and triggers invasive workup.•Current guideline recommendations lack sufficient discriminatory capacity to spare patients from unnecessary interventions.•Development and validation of a nomogram, potentially including urine markers, is recommended. Asymptomatic microhematuria (aMh) remains a diagnostic challenge in urological practice: while aMh is a risk factor of urothelial carcinoma (UC), prevalence of aMh is high. Guidelines were developed to permit risk stratification and reduce diagnostic workload. This study investigates the efficacy of several recommendations. Sixty hundred eight patients with newly diagnosed aMh without previous UC from an academic referral center (A; n = 320) and a private outpatient clinic (B; n = 288) were included. All patients underwent clinical workup including medical history, urine cytology, upper tract imaging and cystoscopy. Eleven former and current guidelines were applied to each patient individually; every patient was classified as either low risk (no further workup recommended) or high risk. Furthermore, a recently developed nomogram for hematuria assessment was included. The cohort comprised 142 females and 466 males (mean age 62 [range 18–92] years). Sixty-one patients (10.0%) were diagnosed with UC. Excluding the Swedish and recent NICE guideline generally advising against urologic workup, application of 9 other recommendations would have diagnosed all UCs and saved 1.6% to 16.1% of patients from workup. For the 2020 US guideline, solely applied to cohort B, 10.6% of patients were classified as low risk. The use of the nomogram would have saved 17.1% to 25% of patients from workup. Practical relevance of current guidelines is limited as they do not sufficiently identify patients not requiring clinical work up. Thus, guideline adherence may trigger overdiagnosis and even overtreatment. New ways of risk stratification are needed to improve aMh assessment.</description><identifier>ISSN: 1078-1439</identifier><identifier>EISSN: 1873-2496</identifier><identifier>DOI: 10.1016/j.urolonc.2022.08.011</identifier><identifier>PMID: 36274029</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Bladder cancer ; Carcinoma, Transitional Cell - complications ; Diagnostic Imaging - adverse effects ; Disease management ; Female ; Guidelines ; Hematuria - diagnosis ; Hematuria - epidemiology ; Hematuria - etiology ; Humans ; Male ; Microhematuria ; Middle Aged ; Nomogram ; Risk Factors ; Urinary Bladder Neoplasms - diagnosis ; Young Adult</subject><ispartof>Urologic oncology, 2023-05, Vol.41 (5), p.254.e1-254.e8</ispartof><rights>2022 Elsevier Inc.</rights><rights>Copyright © 2022 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c313t-3ccd2367a29aa877492e46b7ecc78aeeec460244534715b6d898d3078e714d393</cites><orcidid>0000-0002-4004-1857</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.urolonc.2022.08.011$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36274029$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kuckuck, Eva Charlotte</creatorcontrib><creatorcontrib>Hennenlotter, Jörg</creatorcontrib><creatorcontrib>Todenhöfer, Tilman</creatorcontrib><creatorcontrib>Brünn, Lenuta-Ancuta</creatorcontrib><creatorcontrib>Rass, Georg-Christian</creatorcontrib><creatorcontrib>Stenzl, Arnulf</creatorcontrib><creatorcontrib>Hakenberg, Oliver W.</creatorcontrib><creatorcontrib>Roghmann, Florian</creatorcontrib><creatorcontrib>Goebell, Peter J.</creatorcontrib><creatorcontrib>Grimm, Marc-Oliver</creatorcontrib><creatorcontrib>Pycha, Armin</creatorcontrib><creatorcontrib>Bolenz, Christian</creatorcontrib><creatorcontrib>Burger, Maximilian</creatorcontrib><creatorcontrib>Benderska-Söder, Natalya</creatorcontrib><creatorcontrib>Schmitz-Dräger, Bernd J.</creatorcontrib><title>Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuria</title><title>Urologic oncology</title><addtitle>Urol Oncol</addtitle><description>•Asymptomatic microhematuria is a frequent condition and triggers invasive workup.•Current guideline recommendations lack sufficient discriminatory capacity to spare patients from unnecessary interventions.•Development and validation of a nomogram, potentially including urine markers, is recommended. Asymptomatic microhematuria (aMh) remains a diagnostic challenge in urological practice: while aMh is a risk factor of urothelial carcinoma (UC), prevalence of aMh is high. Guidelines were developed to permit risk stratification and reduce diagnostic workload. This study investigates the efficacy of several recommendations. Sixty hundred eight patients with newly diagnosed aMh without previous UC from an academic referral center (A; n = 320) and a private outpatient clinic (B; n = 288) were included. All patients underwent clinical workup including medical history, urine cytology, upper tract imaging and cystoscopy. Eleven former and current guidelines were applied to each patient individually; every patient was classified as either low risk (no further workup recommended) or high risk. Furthermore, a recently developed nomogram for hematuria assessment was included. The cohort comprised 142 females and 466 males (mean age 62 [range 18–92] years). Sixty-one patients (10.0%) were diagnosed with UC. Excluding the Swedish and recent NICE guideline generally advising against urologic workup, application of 9 other recommendations would have diagnosed all UCs and saved 1.6% to 16.1% of patients from workup. For the 2020 US guideline, solely applied to cohort B, 10.6% of patients were classified as low risk. The use of the nomogram would have saved 17.1% to 25% of patients from workup. Practical relevance of current guidelines is limited as they do not sufficiently identify patients not requiring clinical work up. Thus, guideline adherence may trigger overdiagnosis and even overtreatment. New ways of risk stratification are needed to improve aMh assessment.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Bladder cancer</subject><subject>Carcinoma, Transitional Cell - complications</subject><subject>Diagnostic Imaging - adverse effects</subject><subject>Disease management</subject><subject>Female</subject><subject>Guidelines</subject><subject>Hematuria - diagnosis</subject><subject>Hematuria - epidemiology</subject><subject>Hematuria - etiology</subject><subject>Humans</subject><subject>Male</subject><subject>Microhematuria</subject><subject>Middle Aged</subject><subject>Nomogram</subject><subject>Risk Factors</subject><subject>Urinary Bladder Neoplasms - diagnosis</subject><subject>Young Adult</subject><issn>1078-1439</issn><issn>1873-2496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEuPFCEQgInRuA_9CRqOXrrlNUCfjNnV1WQTL3omDNQ4TLqbFug18--tyYxePVFUfUVRHyFvOOs54_r9oV9LHvMcesGE6JntGefPyDW3RnZCDfo5xszYjis5XJGbWg-McWU5f0mupBZGMTFck3qfaihpSrNv6Qlo8IsPqR1p3tGfa4owphlogZCnCeaIUJ4rTTNte6C-VqgV8-2EL1jEsNLfqe2xdpyWlidMBjqlUPIe8LKW5F-RFzs_Vnh9OW_Jj8-fvt996R6_PXy9-_jYBcll62QIUUhtvBi8t8aoQYDSWwMhGOsBICjNhFIbqQzfbHW0g40SVwbDVZSDvCXvzu8uJf9aoTY34bIwjn6GvFYnjLBc6WGjEd2cUfxnrQV2bkEpvhwdZ-7k2x3cxbc7-XbMOvSNfW8vI9btBPFf11_BCHw4A4CLPiUorga0FCAmlNpczOk_I_4AA2KXFw</recordid><startdate>202305</startdate><enddate>202305</enddate><creator>Kuckuck, Eva Charlotte</creator><creator>Hennenlotter, Jörg</creator><creator>Todenhöfer, Tilman</creator><creator>Brünn, Lenuta-Ancuta</creator><creator>Rass, Georg-Christian</creator><creator>Stenzl, Arnulf</creator><creator>Hakenberg, Oliver W.</creator><creator>Roghmann, Florian</creator><creator>Goebell, Peter J.</creator><creator>Grimm, Marc-Oliver</creator><creator>Pycha, Armin</creator><creator>Bolenz, Christian</creator><creator>Burger, Maximilian</creator><creator>Benderska-Söder, Natalya</creator><creator>Schmitz-Dräger, Bernd J.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4004-1857</orcidid></search><sort><creationdate>202305</creationdate><title>Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuria</title><author>Kuckuck, Eva Charlotte ; Hennenlotter, Jörg ; Todenhöfer, Tilman ; Brünn, Lenuta-Ancuta ; Rass, Georg-Christian ; Stenzl, Arnulf ; Hakenberg, Oliver W. ; Roghmann, Florian ; Goebell, Peter J. ; Grimm, Marc-Oliver ; Pycha, Armin ; Bolenz, Christian ; Burger, Maximilian ; Benderska-Söder, Natalya ; Schmitz-Dräger, Bernd J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c313t-3ccd2367a29aa877492e46b7ecc78aeeec460244534715b6d898d3078e714d393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Bladder cancer</topic><topic>Carcinoma, Transitional Cell - complications</topic><topic>Diagnostic Imaging - adverse effects</topic><topic>Disease management</topic><topic>Female</topic><topic>Guidelines</topic><topic>Hematuria - diagnosis</topic><topic>Hematuria - epidemiology</topic><topic>Hematuria - etiology</topic><topic>Humans</topic><topic>Male</topic><topic>Microhematuria</topic><topic>Middle Aged</topic><topic>Nomogram</topic><topic>Risk Factors</topic><topic>Urinary Bladder Neoplasms - diagnosis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kuckuck, Eva Charlotte</creatorcontrib><creatorcontrib>Hennenlotter, Jörg</creatorcontrib><creatorcontrib>Todenhöfer, Tilman</creatorcontrib><creatorcontrib>Brünn, Lenuta-Ancuta</creatorcontrib><creatorcontrib>Rass, Georg-Christian</creatorcontrib><creatorcontrib>Stenzl, Arnulf</creatorcontrib><creatorcontrib>Hakenberg, Oliver W.</creatorcontrib><creatorcontrib>Roghmann, Florian</creatorcontrib><creatorcontrib>Goebell, Peter J.</creatorcontrib><creatorcontrib>Grimm, Marc-Oliver</creatorcontrib><creatorcontrib>Pycha, Armin</creatorcontrib><creatorcontrib>Bolenz, Christian</creatorcontrib><creatorcontrib>Burger, Maximilian</creatorcontrib><creatorcontrib>Benderska-Söder, Natalya</creatorcontrib><creatorcontrib>Schmitz-Dräger, Bernd J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kuckuck, Eva Charlotte</au><au>Hennenlotter, Jörg</au><au>Todenhöfer, Tilman</au><au>Brünn, Lenuta-Ancuta</au><au>Rass, Georg-Christian</au><au>Stenzl, Arnulf</au><au>Hakenberg, Oliver W.</au><au>Roghmann, Florian</au><au>Goebell, Peter J.</au><au>Grimm, Marc-Oliver</au><au>Pycha, Armin</au><au>Bolenz, Christian</au><au>Burger, Maximilian</au><au>Benderska-Söder, Natalya</au><au>Schmitz-Dräger, Bernd J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuria</atitle><jtitle>Urologic oncology</jtitle><addtitle>Urol Oncol</addtitle><date>2023-05</date><risdate>2023</risdate><volume>41</volume><issue>5</issue><spage>254.e1</spage><epage>254.e8</epage><pages>254.e1-254.e8</pages><issn>1078-1439</issn><eissn>1873-2496</eissn><abstract>•Asymptomatic microhematuria is a frequent condition and triggers invasive workup.•Current guideline recommendations lack sufficient discriminatory capacity to spare patients from unnecessary interventions.•Development and validation of a nomogram, potentially including urine markers, is recommended. Asymptomatic microhematuria (aMh) remains a diagnostic challenge in urological practice: while aMh is a risk factor of urothelial carcinoma (UC), prevalence of aMh is high. Guidelines were developed to permit risk stratification and reduce diagnostic workload. This study investigates the efficacy of several recommendations. Sixty hundred eight patients with newly diagnosed aMh without previous UC from an academic referral center (A; n = 320) and a private outpatient clinic (B; n = 288) were included. All patients underwent clinical workup including medical history, urine cytology, upper tract imaging and cystoscopy. Eleven former and current guidelines were applied to each patient individually; every patient was classified as either low risk (no further workup recommended) or high risk. Furthermore, a recently developed nomogram for hematuria assessment was included. The cohort comprised 142 females and 466 males (mean age 62 [range 18–92] years). Sixty-one patients (10.0%) were diagnosed with UC. Excluding the Swedish and recent NICE guideline generally advising against urologic workup, application of 9 other recommendations would have diagnosed all UCs and saved 1.6% to 16.1% of patients from workup. For the 2020 US guideline, solely applied to cohort B, 10.6% of patients were classified as low risk. The use of the nomogram would have saved 17.1% to 25% of patients from workup. Practical relevance of current guidelines is limited as they do not sufficiently identify patients not requiring clinical work up. Thus, guideline adherence may trigger overdiagnosis and even overtreatment. New ways of risk stratification are needed to improve aMh assessment.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>36274029</pmid><doi>10.1016/j.urolonc.2022.08.011</doi><orcidid>https://orcid.org/0000-0002-4004-1857</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1078-1439
ispartof Urologic oncology, 2023-05, Vol.41 (5), p.254.e1-254.e8
issn 1078-1439
1873-2496
language eng
recordid cdi_proquest_miscellaneous_2728146956
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Adolescent
Adult
Aged
Aged, 80 and over
Bladder cancer
Carcinoma, Transitional Cell - complications
Diagnostic Imaging - adverse effects
Disease management
Female
Guidelines
Hematuria - diagnosis
Hematuria - epidemiology
Hematuria - etiology
Humans
Male
Microhematuria
Middle Aged
Nomogram
Risk Factors
Urinary Bladder Neoplasms - diagnosis
Young Adult
title Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuria
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T06%3A01%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discriminative%20capacity%20of%20guideline%20recommendations%20in%20the%20assessment%20of%20patients%20with%20asymptomatic%20microhematuria&rft.jtitle=Urologic%20oncology&rft.au=Kuckuck,%20Eva%20Charlotte&rft.date=2023-05&rft.volume=41&rft.issue=5&rft.spage=254.e1&rft.epage=254.e8&rft.pages=254.e1-254.e8&rft.issn=1078-1439&rft.eissn=1873-2496&rft_id=info:doi/10.1016/j.urolonc.2022.08.011&rft_dat=%3Cproquest_cross%3E2728146956%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2728146956&rft_id=info:pmid/36274029&rft_els_id=S1078143922003040&rfr_iscdi=true